Every material Form 8-K Colgate-Palmolive filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Colgate-Palmolive reported third quarter 2026 net sales of $5.37 billion, representing a 4.6% increase year over year, with GAAP earnings per share of $0.94. Driven by ongoing sales momentum and margin expansion, the company raised its full-year earnings per share growth guidance to 5% to 7% on a non-GAAP basis.
Net sales rose 4.6% to $5,369 million for the quarter ended September 30, 2026.
GAAP EPS increased 3% to $0.94, while Base Business EPS grew 7% to $0.97.
Full-year 2026 organic sales growth is now expected to be broadly in line with its nine-month performance.
Colgate-Palmolive reported second-quarter 2026 net sales of $5,361 million, up 4.9% from $5,110 million, and GAAP diluted EPS of $0.86, down 5% from $0.91. Excluding a $129 million charge tied to its Strategic Growth and Productivity Program, Base Business EPS rose 8% to $0.99, and the company updated its full-year 2026 gross margin and Base Business EPS guidance upward while keeping its sales and GAAP EPS guidance.
Net sales rose 4.9% to $5,361 million; organic sales rose 2.4%, and Total Company operating profit fell 6% to $1,016 million.
GAAP gross profit margin rose 140 basis points to 61.5%; Base Business EPS rose 8% to $0.99 from $0.92.
Full-year 2026 guidance: GAAP and Base Business gross profit margin now expected roughly flat (previously down); Base Business EPS growth now expected mid-single-digit (previously low- to mid-single-digit).
Net sales guidance of up 2% to 6% and GAAP EPS guidance were maintained.
Colgate-Palmolive reported first-quarter 2026 net sales of $5,324 million, up 8.4%, while GAAP diluted EPS fell 6% to $0.80 and base business EPS rose 7% to $0.97. On April 30, 2026, the board expanded its Strategic Growth and Productivity Program, raising estimated cumulative pretax charges to $350 million to $550 million from $200 million to $300 million.
Net sales rose to $5,324 million from $4,911 million; organic sales grew 2.9%.
GAAP diluted EPS was $0.80 versus $0.85; base business EPS was $0.97 versus $0.91.
Program charges now estimated at $350 million to $550 million, with $200 million to $300 million in annual savings once implemented.
Full-year 2026 sales and EPS guidance was maintained, but GAAP and base business gross profit margin is now expected to decline, versus a prior expectation of an increase.
Colgate-Palmolive said its Board elected Betsy Fishbone, currently Executive Vice President and Deputy Chief Legal Officer, as Chief Legal Officer and Secretary, effective June 1, 2026. Jennifer M. Daniels, who has held the role since 2014, plans to retire in 2026 and will become Vice Chair on the same date to oversee an orderly handover.
Betsy Fishbone to become Chief Legal Officer and Secretary effective June 1, 2026
Jennifer M. Daniels, Chief Legal Officer and Secretary since 2014, intends to retire in 2026
Daniels to be elected Vice Chair effective June 1, 2026 to provide for an orderly transition
Board action taken April 8, 2026; filing dated April 9, 2026
Colgate-Palmolive's board elected Christopher S. Boerner, chair and chief executive of Bristol Myers Squibb, as a director effective March 15, 2026. Separately, director Steven A. Cahillane will not stand for reelection at the May 8, 2026 annual meeting because of his new role as chief executive of The Kraft Heinz Company. The filing describes board composition changes only and gives no financial results or operating impact.
Christopher S. Boerner, 55, joins the board effective March 15, 2026; he has been Bristol Myers Squibb CEO since November 2023 and board chair since April 2024
Steven A. Cahillane will not seek reelection to the board at the Annual Meeting of Stockholders on May 8, 2026
Cahillane cited the demands of his new position as CEO of The Kraft Heinz Company
Boerner will receive non-employee director compensation under the program described in the March 26, 2025 proxy statement
Colgate-Palmolive reported fourth quarter 2025 net sales up 5.8% to $5,230 million, but GAAP diluted EPS was $(0.05) versus $0.90 a year earlier, driven by a $794 million after-tax goodwill and intangible asset impairment tied to the skin health business. Excluding these items, Base Business EPS rose 4% to $0.95. The company also guided 2026 net sales growth of 2% to 6% and GAAP double-digit EPS growth.
Q4 2025 net sales rose 5.8% to $5,230 million; organic sales rose 2.2%.
GAAP diluted EPS was $(0.05), down 106%, after a $794 million after-tax impairment charge on skin health goodwill and intangibles.
Base Business EPS rose 4% to $0.95; full-year 2025 GAAP EPS fell 25% to $2.63.
2026 guidance: net sales up 2% to 6%, organic sales growth of 1% to 4%, and GAAP double-digit EPS growth.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Colgate-Palmolive filing is on SEC EDGAR ↗. 8-K briefs of other companies →